Le nostre soluzioni
Pipeline
In Chiesi, il nostro portafoglio prodotti e la nostra pipeline sono focalizzati sullo sviluppo e sull’immissione sul mercato di soluzioni farmaceutiche innovative che migliorino la qualità della vita delle persone, con una particolare attenzione alle nostre aree terapeutiche principali: malattie respiratorie, malattie rare e ultra-rare, neonatologia, special care e primary care.
Questa scelta strategica ci consente di continuare ad ampliare e rafforzare la nostra pipeline attraverso studi che promettono importanti progressi per il futuro della nostra azienda, offrendo al contempo nuove opportunità per quei pazienti con malattie con bisogni non soddisfatti e che sono ancora privi di opzioni terapeutiche per le loro patologie.
Malattie Respiratorie
| Indication / Disease | Active Principle | Formulation | Region | Phase | Alliance / Partnership |
|---|---|---|---|---|---|
| Asthma, COPD | BDP + FF | pMDI, DPI | EU | Post-approval | - |
| Asthma, COPD | BDP + FF + GB | pMDI, DPI | EU | Post-approval | - |
| Asthma, COPD | BDP + FF + GB | pMDI | US | Phase 3 | - |
| Asthma | BDP + FF + GB | DPI | Ex US | Phase 3 | - |
| Asthma, COPD | BDP + FF + GB | pMDI with HFA 152a (Carbon Minimal Inhaler) | Global | Phase 3 | - |
| Asthma, COPD | BDP + FF | pMDI with HFA 152a (Carbon Minimal Inhaler) | Global | Phase 3 | - |
| Asthma | BDP | pMDI with HFA 152a (Carbon Minimal Inhaler) | Selected countries in EU and Ex-EU | Phase 3 | - |
| Bronchiectasis | DDP1i | Oral | Ex - China | Phase 3 | Haisco |
| Bronchiectasis | NEi | DPI | Global | Phase 2 | - |
| Idiopathic pulmonary fibrosis (IPF) | Zampilimab (anti TG-2) | Intravenous (IV) | - | Phase 2 | UCB |
| Idiopathic pulmonary fibrosis (IPF) | DDRi | DPI | Global | Phase 1 | - |
| Pulmunary arterial hypertension (PAH | Seralutnib (GB002) (PDGFRα/β, CSF1R, c-KIT inhibitor) | DPI | Global | Phase 3 | Gossamer Bio |
Malattie Rare
| Indication / Disease | Active Principle | Formulation | Region | Phase | Alliance / Partnership |
|---|---|---|---|---|---|
| Alpha-mannosidosis | Velmanase alfa-tycv | Lyophilized sterile powder for reconstitution with 5ml sterile water for infusion | EU, US | Post-approval | - |
| Alpha-mannosidosis | - | - | Global | Preclinical | Key2Brain |
| Krabbe disease | - | - | Global | Preclinical | Key2Brain |
| Nephropathic cystinosis | Cysteamine bitartrate | Gastro-resistant hard capsules | EU, US | Post-approval | Amgen |
| Fabry disease | Pegunigalsidase alfa-iwxj | IV Solution | EU, UK, US | Post-approval | Protalix Biotherapeutics |
| Fabry disease - pediatric | Pegunigalsidase alfa-iwxj | IV Solution | Global | Phase 2/3 | Protalix Biotherapeutics |
| Fabry disease | Pegunigalsidase alfa-iwxj | IV Solution | Japan | Phase 2/3 | Protalix Biotherapeutics |
| Other inborn errors of metabolism diseases | - | - | Global | Preclinical | Aliada |
| Leber’s Hereditary Optic Neuropathy (LHON) | Idebenone | Flm-coated tablets | EU | Post-approval | - |
| Generalized Lipodystrophy | Metreleptin | Injection | Global | Post-approval | - |
| Partial Lipodystrophy | Metreleptin | Injection | EU | Post-approval | - |
| Partial Lipodystrophy | Metreleptin | Injection | US | Phase 3 | - |
| Acromegaly | Octreotide | Gastro-resistant hard capsules | US | Post-approval | - |
| Homozygous Familial Hypercholesterolemia (HoFH) | Lomitapide | Capsules | EU, US | Post-approval | - |
| Primary Hyperoxalurlia type 1 | - | - | Global | Phase 1/2 | Arbor Biotechnologies |
| Epidermolysis Bullosa (EB) | Birch triterpenes | Topical gel | EU, US | Post-approval | - |
| Epidermolysis Bullosa (EB) | Birch triterpenes | Topical gel | Japan | Phase 3 | - |
| Thalassemia | Deferiprone | Tablets oral solution | EU, US | Post-approval | - |
| Sickle Cell Disease or Other Anaemias | Deferiprone | Tablets oral solution | US | Post-approval | - |
| Adenosine Deaminase - Severe Combined Immune Deficiency | Elapegademase-lvlr | Injection | JP, US | Post-approval | - |
| Other rare diseases | - | - | Global | Preclinical | Arbor Biotechnologies |
Cure Specialistiche e Primarie
| Indication / Disease | Active Principle | Formulation | Region | Phase | Alliance / Partnership |
|---|---|---|---|---|---|
| Neonatal RDS treatment | Poractant alfa | Endotracheopulmonary Instillation sterile Suspension | - | Post-approval | - |
| Treatment of primary apnoea of premature newborns | Caffeine Citrate | Solution for infusion, oral solution | - | Post-approval | - |
| Reduction of blood pressure when oral therapy is not feasible or in perioperative settings | Clevidipine | Emulsion | - | Post-approval | - |
| Anti-platelet; reducing risk of thrombotic cardiovascular events undergoing percutaneous coronary intervention (PCI) | Cangrelor | Lyophilized powder | US, EU | Post-approval | - |
| Prophylaxis of transplant rejection in adult kidney or liver allograft recipients | Tacrolimus | Prolonged-release tablets | - | Post-approval | Veloxis |
| Prevention of bronchopulmonary dysplasia (BPD) | IGF-1 Biologic | Sterile solution for infusion | - | Phase 2b | Oak Hill Bio |
| Treatment of intestinal malabsorption in preterm infants | Insulin | Oral solution | - | Phase 3 | Elgan |